Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa‐Therapy in Parkinson's Disease: A Randomized, Placebo‐Controlled Study ( PREMANDYSK )
Open Access
- 29 November 2025
- journal article
- Published by Wiley in Movement Disorders
- Vol. 41 (3) , 729-740
Abstract
Objective: Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background: While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor complications remain limited. Methods: This 22‐month, multicenter, randomized, placebo‐controlled trial (NCT01538329) enrolled early PD patients on stable levodopa (≥150 mg/day for ≤1 year) without motor complications. The study included three double‐blind phases: an 18‐month treatment phase with adjunct amantadine‐IR (200 mg/day) or placebo (Period 1), a 3‐month delayed‐start phase where all participants received amantadine‐IR (Period 2), and a 1‐month washout with placebo (Period 3). The primary outcome was dyskinesia incidence at month 18; secondary outcomes included dyskinesia rates at the end of Periods 2 and 3 to assess potential long‐lasting mechanisms of the drug. Exploratory outcomes investigated the potential effects of amantadine‐IR on motor and non‐motor symptoms and quality of life. Results: A total of 207 patients were randomized to amantadine‐IR (N = 99) or placebo (N = 108). Significantly fewer patients in the amantadine‐IR group developed dyskinesia versus placebo during Period 1 (11% vs. 22%, P = 0.025), while the mean daily dose of levodopa (95% CI) increased by 70 (21–119) mg less ( P = 0.005). The proportion of patients with dyskinesia was less in the amantadine‐IR group versus placebo at the end of Periods 2 and 3, but the difference was not statistically significant (12% vs. 20%, P = 0.13 and 16% vs. 22%, P = 0.23, respectively). Mild but significant positive effects on freezing of gait, fatigue, and quality of life were observed during Period 1. The safety profile of amantadine‐IR was in line with previous reports. Conclusions: Adjunctive amantadine‐IR in early PD halved dyskinesia incidence over 18 months. Long‐lasting mechanisms could not be demonstrated and merit further investigation. Exploratory positive findings on the potential benefit of amantadine‐IR on symptoms like freezing of gait and fatigue also call for further investigation. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords
Funding Information
- Université de Toulouse
This publication has 29 references indexed in Scilit:
- Levodopa‐Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5‐Year Follow‐Up StudyMovement Disorders Clinical Practice, 2024
- International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's diseaseMovement Disorders, 2018
- Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's diseaseMovement Disorders, 2013
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD studyAnnals of Neurology, 2010
- The Unified Dyskinesia Rating Scale: Presentation and clinimetric profileMovement Disorders, 2008
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot studyMovement Disorders, 2007
- Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessmentMovement Disorders, 2005
- Assessing quality of life in Parkinson's disease: Can a short‐form questionnaire be useful?Movement Disorders, 2003